Estimating the direct and indirect costs for community-dwelling patients with schizophrenia: Schizophrenia-related costs for community-dwellers
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
To estimate the schizophrenia-related direct and indirect costs for community-dwelling Americans sampled in the Medical Expenditure Panel Survey (MEPS) from the societal perspective. Patients diagnosed with a schizophrenic disorder (International Classification of Disease 9th Revision (ICD-9) code 295) or other non-organic psychoses (ICD-9 code 298) between 1 January 2005 and 31 December 2008 were identified from the MEPS database. The following categories were included in calculating the schizophrenia-related direct medical costs: inpatient hospitalizations, prescription medications and hospital outpatient, emergency department, physician office, and home healthcare visits. The indirect costs were calculated using the human capital approach and included lost productivity due to missed work, reduced employment, premature death and caregivers’ costs. To account for the complex multistage sampling design of the MEPS, all statistical analyses were conducted using the survey procedure of SAS version 9.2. We identified 348 patients who represent 3.03 million community-dwelling schizophrenia patients in the USA between 2005 and 2008. The estimated direct cost from 2005–2008 was US$17.1 billion, or approximately US$4 billion per year, with a mean annual cost per patient of US$5984. The indirect costs over the same 4-year period amounted to US$74.74 billion, or approximately US$18.68 billion per year, with a mean annual cost per patient of US$24 664. Assuming equal utilization each year, the annual total costs were approximately US$23 billion. The financial burden imposed by schizophrenia was disproportionately high. The mean annual prevalence of schizophrenia in the community was about 0.25% while the annual costs were about US$23 billion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121 · cited 1×
“Because only schizophrenia-related costs were included in the current analyses, costs due to comorbidities (such as diabetes, metabolic syndrome, cardiovascular diseases and other psychiatric comorbidities including substance abuse disorders) related to schizophrenia are not included.([35]) This leads to an underestim…”
BackgroundA Prospective Analysis of Work in Schizophrenia
Mueser, K. T., Salyers, M. P., & Mueser, P. R. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006874 · Cited by 381
Review: Mortality in schizophrenia: a measurable clinical endpoint
Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185 · cited 1×
“Premature mortality/suicide Almost 40% of the deaths in schizophrenia patients are due to suicide.([21]) A study by Saha et al.”
BackgroundSchizophrenia and Older Adults: An Overview: Directions for Research and Policy
Cohen, C. I., Cohen, G. D., Blank, K., Gaitz, C., Katz, I. R., Leuchter, A., Maletta, G., Meyers, B., Sakauye, K., & Shamoian, C. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00003 · Cited by 112
Cited by
Global economic burden of schizophrenia: a systematic review
Chaiyakunapruk, N., Chong, H. Y., Teoh, S. L., Wu, D. B.-C., Kotirum, S., & Chiou, C.-F. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s96649 · Cited by 643
Simeone, J. C., Ward, A. J., Rotella, P., Collins, J., & Windisch, R. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0578-7 · Cited by 327
“In total, 65 primary studies [14–78] and 16 related publications [79–94] published from 1990–2013 were identified for inclusion in this review.”
BackgroundKotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2022.2157596 · Cited by 57
Families and medication use and adherence among Latinos with schizophrenia
Hernandez, M., & Barrio, C. (2017) · Journal of Mental Health · doi:10.1080/09638237.2016.1222061 · Cited by 14
Metadata
- Authors
- Desai, P. R., Lawson, K. A., Barner, J. C., & Rascati, K. L.
- Venue
- Journal of Pharmaceutical Health Services Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-16
- Volume
- 4
- Issue
- 4
- Pages
- 187-194
- ISSN
- 1759-8885 (ISSN-L)
- OpenAlex
- W1838285883
- Cited by
- 99
- References
- 7
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimating the direct and indirect costs for community-dwelling patients with schizophrenia: Schizophrenia-related costs for community-dwellers. https://app.cochat.ai/papers/10.1111/jphs.12027
- The paper
- Desai, P. R., Lawson, K. A., Barner, J. C., & Rascati, K. L. (2013). Estimating the direct and indirect costs for community-dwelling patients with schizophrenia: Schizophrenia-related costs for community-dwellers. Journal of Pharmaceutical Health Services Research. https://doi.org/10.1111/jphs.12027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.